Neutropenia Pipeline Insight
DelveInsight’s, “Neutropenia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in Neutropenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Neutropenia is a blood condition characterized by low levels of neutrophils, which are white blood cells that protect your body from infections. There are four types of neutropenia: Congenital neutropenia, cyclic neutropenia, autoimmune neutropenia, Idiopathic neutropenia. Neutropenia symptoms can range from mild to severe. The lower the level of neutrophils, the more intense the symptoms. Typical symptoms include: fever, pneumonia, sinus infections, otitis media (ear infection), gingivitis (gum inflammation), omphalitis (navel infection) and skin abscesses. Severe congenital neutropenia can have serious symptoms. The symptoms often include bacterial infections. These infections can grow on the skin and in the digestive and respiratory systems. The symptoms of cyclic neutropenia recur in 3-week cycles. Infections can increase when neutrophil levels fall. Neutropenia can be triggered by: chemotherapy, radiation therapy, the use of certain drugs.
The companies and academics are working to assess challenges and seek opportunities that could influence Neutropenia R&D. The therapies under development are focused on novel approaches for Neutropenia.
Neutropenia Emerging Drugs Chapters
This segment of the Neutropenia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Neutropenia Emerging Drugs
Plinabulin: BeyondSpring Pharmaceuticals
Plinabulin, BeyondSpring’s lead asset, is a selective immune-modulating microtubule-binding agent (SIMBA). A global Phase 3 clinical trial in CIN (PROTECTIVE-2) with plinabulin in combination with pegfilgrastim versus pegfilgrastim alone has been completed and is the basis for an NDA filing in the U.S. and China for the prevention of CIN. In this trial, plinabulin reduced the “neutropenia vulnerability gap” associated with G-CSF therapy alone.
In March, 2021, BeyondSpring announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and the China National Medical Products Administration (NMPA) for use of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN).
Romyelocel-L: Cellerant Therapeutics
Romyelocel-L, a composition of human myeloid progenitor cells, can be administered to provide a source of mature neutrophils and provide transient innate immunity until the patient’s own immune system recovers.
Romyelocel-L is being developed to prevent bacterial and fungal infections in patients with prolonged neutropenia. Romyelocel-L has been evaluated in three clinical trials to date. In a randomized, controlled Phase 2 trial (NCT02282215), romyelocel-L significantly reduced infections and days in hospital. Romyelocel-L has shown an acceptable safety profile in the three clinical trials, with a total of 151 subjects aged 12 years and above exposed to romyelocel-L.
Further product details are provided in the report……..
Neutropenia: Therapeutic Assessment
This segment of the report provides insights about the different Neutropenia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Neutropenia
There are approx. 20+ key companies which are developing the Neutropenia. The companies which have their Neutropenia drug candidates in the most advanced stage, i.e. Preregistration include, BeyondSpring Pharmaceuticals.
DelveInsight’s report covers around 30+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Neutropenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Neutropenia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Neutropenia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neutropenia drugs.
Neutropenia Report Insights
- Neutropenia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Neutropenia Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Neutropenia drugs?
- How many Neutropenia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Neutropenia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Neutropenia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Neutropenia and their status?
- What are the key designations that have been granted to the emerging drugs?